Arthropathy

Enveric Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 2023

Retrieved on: 
Tuesday, March 26, 2024
Biotechnology, Pharmaceutical, Health, Mental Health, Depression, Conference, American Chemical Society, Patent, Acceleration, Partnership, HERG, Patient, CNS, Journal, Anxiety, IND, Chemical substance, Addiction, Safety, Therapy, Arthropathy, Medicinal chemistry, Pharmaceutical industry

Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, today provided a corporate update and reported financial results for the fourth quarter of 2023 and fiscal year ended December 31, 2023.

Key Points: 
  • Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, today provided a corporate update and reported financial results for the fourth quarter of 2023 and fiscal year ended December 31, 2023.
  • “The fourth quarter of 2023 and early 2024 was a significant period for Enveric, highlighted by the selection of EB-003 as our lead development candidate.
  • Continued to strengthen our intellectual property portfolio, receiving ten patent issuances from the United States Patent and Trademark Office.
  • The gross proceeds to the Company from the two warrant exercises totaled approximately $4.5 million.

Enveric Biosciences Signs Non-Binding Term Sheets to Pursue the Exclusive Out-Licensing of New Chemical Entities for Pharmaceutical and Non-Pharmaceutical Applications in Joint Disease

Retrieved on: 
Tuesday, March 19, 2024
Biotechnology, Pharmaceutical, Other Manufacturing, Health, Mental Health, Chemicals, Plastics, Manufacturing, Other Health, Depression, Cannabinoid, Rheumatoid arthritis, Patient, Anxiety, IND, Addiction, Pathology, Therapy, Osteoarthritis, Arthropathy, Steroid, Pharmaceutical industry

The compounds are new chemical entities that include cannabinoids in conjugate form with COX-2 inhibitors and cannabinoids in conjugate form with selected steroids.

Key Points: 
  • The compounds are new chemical entities that include cannabinoids in conjugate form with COX-2 inhibitors and cannabinoids in conjugate form with selected steroids.
  • Royalty rates could range from 2.5% up to 10% on future sales, depending on meeting certain sales criteria.
  • Together, through the out-licensing of the two assets and meeting various development and sales milestones, Enveric could potentially receive milestone payments that total up to approximately $82 million.
  • “We look forward to working with our partner, and we are confident in their leadership and capabilities to continue the development of these compounds for both pharmaceutical and non-pharmaceutical applications to advance joint disease treatment options for patients.

Global Autologous Matrix-Induced Chondrogenesis (AMIC) Strategic Industry Report 2024: Market to Reach $278 Million by 2030 - Growing Demand for Minimally-Invasive Surgeries to Propel Market Growth - ResearchAndMarkets.com

Retrieved on: 
Thursday, February 29, 2024
Biotechnology, Health, Surgery, Autotransplantation, Arthropathy, Prevalence, Growth, Hyaluronic acid, Collagen, AMIC, Pharmaceutical industry

The "Autologous Matrix-Induced Chondrogenesis (AMIC) - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Autologous Matrix-Induced Chondrogenesis (AMIC) - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.
  • The global market for Autologous Matrix-Induced Chondrogenesis (AMIC) estimated at US$153 Million in the year 2022, is projected to reach a revised size of US$278 Million by 2030, growing at a CAGR of 7.7% over the analysis period 2022-2030.
  • Collagen, one of the segments analyzed in the report, is projected to record a 7.5% CAGR and reach US$158.8 Million by the end of the analysis period.
  • The Autologous Matrix-Induced Chondrogenesis (AMIC) market is poised for growth due to the increasing prevalence of joint disorders.

Highlights of Dr. David Hunter’s Oral Presentation at ACR’s Late Breaking Abstracts Session

Retrieved on: 
Monday, November 20, 2023
Arthropathy, TLC, ACR, DSP, Osteoarthritis, SAN, University, Week, Stiffness, American College, Patient, Safety, Pharmaceutical industry

In his late-breaking oral presentation, Prof. Hunter provided background on osteoarthritis, introduced TLC599, and presented data showing TLC599’s potential to be a better treatment for managing osteoarthritis knee pain than currently available treatments.

Key Points: 
  • In his late-breaking oral presentation, Prof. Hunter provided background on osteoarthritis, introduced TLC599, and presented data showing TLC599’s potential to be a better treatment for managing osteoarthritis knee pain than currently available treatments.
  • Non-surgical treatments are limited, but include physical therapy, oral analgesics, NSAIDSs, and intraarticular injections.
  • While steroid injections can provide pain relief and improve mobility, the duration of effect can be short and unpredictable.
  • These positive Phase 3 results suggest TLC599 could become an important new therapeutic option for patients with osteoarthritis of the knee.

AM-Pharma Announces Positive Clinical Data From Phase 1b Study Evaluating Ilofotase Alfa in Hypophosphatasia Patients

Retrieved on: 
Wednesday, October 11, 2023
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Bone disease, Vancouver Convention Centre, Pharmacokinetics, Doctor of Philosophy, Biomarker, MD, Society, Data, DSM-IV codes, PLP, Safety, University, ALPL, Disease, Arthropathy, Patient, HPP, PDT, Enzyme, Pyrophosphate, Hypophosphatasia, American Society for Bone and Mineral Research, Muscle weakness, Enzyme replacement therapy, Pharmaceutical industry

AM-Pharma B.V. today announced positive clinical results from the Phase 1b study evaluating the company’s proprietary recombinant alkaline phosphatase, ilofotase alfa, as potential enzyme replacement therapy in adult hypophosphatasia (HPP) patients.

Key Points: 
  • AM-Pharma B.V. today announced positive clinical results from the Phase 1b study evaluating the company’s proprietary recombinant alkaline phosphatase, ilofotase alfa, as potential enzyme replacement therapy in adult hypophosphatasia (HPP) patients.
  • Patients were followed for 10 days after dosing to evaluate changes in the biochemical fingerprint of HPP, safety and tolerability.
  • In addition, ilofotase alfa was well-tolerated with pharmacokinetics consistent with observations from previous clinical studies.
  • "The encouraging early results confirming dose-dependent reductions of PLP and PPi levels upon treatment with ilofotase alfa underline the compound's therapeutic potential in that indication and I'm looking forward to evaluating ilofotase alfa in next stage clinical studies."

Athersys Licenses its Animal Health Assets to Ardent Animal Health

Retrieved on: 
Tuesday, October 3, 2023
Stem Cells, Medical Supplies, Biotechnology, Other Health, Health, General Health, Pharmaceutical, Pets, Genetics, Consumer, Veterinary, Partnership, Arthropathy, Regenerative medicine, Animal, Veterinary medicine, Pharmaceutical industry, Ardent

Athersys, Inc. (Nasdaq: ATHX), a cell therapy and regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, and Multipotent Adult Progenitor Cell (MAPC®) technology for equine, canine, and feline health applications, announces the signing of a licensing agreement with Ardent Animal Health (Ardent).

Key Points: 
  • Athersys, Inc. (Nasdaq: ATHX), a cell therapy and regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, and Multipotent Adult Progenitor Cell (MAPC®) technology for equine, canine, and feline health applications, announces the signing of a licensing agreement with Ardent Animal Health (Ardent).
  • Under the terms of the agreement, Athersys will receive an initial fee from Ardent in exchange for an exclusive license to Athersys’ Multipotent Adult Progenitor Cell (MAPC®) technology for non-human mammal applications in the United States.
  • Athersys has also granted Ardent rights of first refusal to be the exclusive distributor for Athersys’ novel cryogenic storage system, the Secure Integrated Freezer Unit (SIFU) in the United States animal health space.
  • This agreement recognizes the progress we’ve made in preclinical research and manufacturing of MAPC for animal health and provides Ardent a solid foundation to build on,” stated Dan Camardo, Chief Executive Officer of Athersys.

Implantable Medical Devices Market to grow by USD 51.1 billion from 2022-2027 | North America to account for 45% of market growth - Technavio

Retrieved on: 
Tuesday, September 26, 2023
LivaNova, Prevalence, Osteoporosis, Abbott Laboratories, Tetraplegia, Segment, National Center for Spinal Disorders, SE, Stryker Corporation, Rheumatoid arthritis, Dental implant, Gout, Hip, Zimmer Biomet, Lupus, Cardinal Health, USD, CDC, Medial knee injuries, Boston Scientific, Circulatory system, Growth, Assurant, Orthopedic surgery, Trauma, Clifton Springs Hospital & Clinic, Arthritis, Hospital, NuVasive, Research, Arthropathy, Knee, Laboratory, AbbVie, Ophthalmic, ROW, Korea Disease Control and Prevention Agency, Fibromyalgia, Medtronic, Medical device, Retail, Application, Geography

NEW YORK, Sept. 25, 2023 /PRNewswire/ -- The implantable medical devices market size is expected to grow by USD 51.1 billion from 2022 to 2027.

Key Points: 
  • NEW YORK, Sept. 25, 2023 /PRNewswire/ -- The implantable medical devices market size is expected to grow by USD 51.1 billion from 2022 to 2027.
  • Hence, such factors drive the growth of the implantable medical devices market during the forecast period.
  • Detailed information on factors that will drive the growth of the implantable medical devices market between 2022 and 2027.
  • Growth of the implantable medical devices market across North America, Europe, Asia, and ROW
    Comprehensive analysis of factors that will challenge the growth of implantable medical devices market vendors.

Ark-La-Tex Health Center Introduces New Advanced Regenerative Medicine Therapy with Unparalleled Results

Retrieved on: 
Thursday, September 21, 2023
Brother, Face, Quality of life, Hope, Veteran, Science, Regenerative medicine, Pain, Patient, Brothers In Arms Foundation, Health, Chronic pain, Arthropathy, Hospital, Nursing, Texarkana metropolitan area

TEXARKANA, Ark., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Ark-la-Tex Health Center is now offering a revolutionary new method in healing, called “regenerative medicine”.

Key Points: 
  • TEXARKANA, Ark., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Ark-la-Tex Health Center is now offering a revolutionary new method in healing, called “regenerative medicine”.
  • This leading healthcare facility is now at the forefront of revolutionary therapy techniques, solidifying its position as the go-to destination for regenerative medicine.
  • The Ark-la-Tex Health Center is proud to be one of the few facilities in the Texarkana area offering these cutting-edge regenerative therapy techniques .
  • As Dr. Raker explains, "Our mission at Ark-la-Tex Health Center is to provide hope and healing through advanced regenerative medicine.

Global Musculoskeletal Disorders Drugs Market to Surge, Projected to Reach $109.4 Billion by 2029 with 4.2% CAGR - ResearchAndMarkets.com

Retrieved on: 
Wednesday, September 13, 2023
Health, Pharmaceutical, Online, Osteoarthritis, Prevalence, Route of administration, Arena Pharmaceuticals, Arthritis, Kirin-Amgen Inc v Hoechst Marion Roussel Ltd, Analgesic, COVID-19, Distribution (marketing), Ageing, Microsoft, Bone, DSM-IV codes, MicroRNA, Life expectancy, Musculoskeletal disorder, Hospital, Arthropathy, Market, Administration, Back pain, Disease-modifying antirheumatic drug, Compound annual growth rate, UCB, Acquisition, AbbVie, Eli Lilly and Company, Pharmacy, Human musculoskeletal system, Growth, Johnson & Johnson, Immunology, Merck & Co., Novartis, Pharmaceutical industry, Agriculture, Pfizer

The global Musculoskeletal Disorders Drugs Market is set to witness significant expansion, projected to reach a substantial value of $109.4 billion by 2029, with a steady Compound Annual Growth Rate (CAGR) of 4.2% during the forecast period.

Key Points: 
  • The global Musculoskeletal Disorders Drugs Market is set to witness significant expansion, projected to reach a substantial value of $109.4 billion by 2029, with a steady Compound Annual Growth Rate (CAGR) of 4.2% during the forecast period.
  • The rise in life expectancy and aging population leads to a surge in musculoskeletal diseases, boosting the demand for treatments and subsequently propelling market expansion.
  • High Prevalence of Musculoskeletal Diseases: Over 150 diseases and conditions fall under the category of musculoskeletal disorders, affecting individuals globally.
  • The prevalence of these disorders, such as arthritis, osteoarthritis, and back pain, drives the demand for drugs and treatment options.

Moximed’s MISHA™ Knee System Treats First Commercial Patients in United States

Retrieved on: 
Wednesday, September 6, 2023
General Health, Health, Medical Devices, Surgeon, University, Terminal, Orthopedic surgery, Oregon Health & Science University, Quality of life, Arthropathy, Hamstring, Cartilage, Trial of the century, Pain, OA, Hospital for Special Surgery, Rehabilitation, Motion, Walking, Standard of care, Patient, Physician, School, SUNY Downstate Health Sciences University, HSS, ISA, Hospital, Ageing, Meniscus, FDA, Chronic pain, Osteoarthritis, University of Virginia, Female, Knee, Dentistry, DRS

Until the MISHA Knee System became available in April 2023, physicians and many patients had limited treatment options when conservative treatments failed.

Key Points: 
  • Until the MISHA Knee System became available in April 2023, physicians and many patients had limited treatment options when conservative treatments failed.
  • Prior to the MISHA Knee System being available, I had no good options for this patient.
  • For these patients, total knee replacement is a reluctant option, as it is an end-stage treatment for end-stage disease.
  • OA patients without end-stage disease seek options that preserve their knee, activity level, and quality of life.